PNZ5
PNZ5 is a potent and isoxazole-based pan-BET inhibitor with high selectivity and potency similar to the well-established (+) -JQ1, with a KD of 5.43 nM for BRD4 (1) [1].
Product Specifications
CAS Number
[1629277-36-6]
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pnz5.html
Purity
99.61
Solubility
10 mM in DMSO
Smiles
CN1C(C2=CC=C(C3=C(C)ON=C3C)C=C2[C@@]1(C4=CC=CC=C4)[H])=O
Molecular Formula
C20H18N2O2
Molecular Weight
318.37
References & Citations
[1]Montenegro RC, et al. BET inhibition as a new strategy for the treatment of gastric cancer. Oncotarget. 2016 Jul 12;7 (28) :43997-44012.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2042195-01 0.1 mL
Cy3-Linked Polyclonal Antibody to Myelin Oligodendrocyte Glycoprotein (MOG)
Ask
View Details 
MBS2042195-02 0.2 mL
Cy3-Linked Polyclonal Antibody to Myelin Oligodendrocyte Glycoprotein (MOG)
Ask
View Details MBS2042195-03 0.5 mL
Cy3-Linked Polyclonal Antibody to Myelin Oligodendrocyte Glycoprotein (MOG)
Ask
View Details MBS2042195-04 1 mL
Cy3-Linked Polyclonal Antibody to Myelin Oligodendrocyte Glycoprotein (MOG)
Ask
View Details